Preclinical Product
Development

We design and validate robust biochemical and cell-based assays to measure biological activity, potency, and mechanism of action. Assay platforms are optimized for reproducibility, scalability, and regulatory alignment. 

Our high-throughput screening infrastructure enables rapid evaluation of compound libraries and biologic candidates. Automated screening systems support hit identification, lead optimization, and structure–activity relationship analysis. 

Data science underpins candidate optimization and decision-making. We integrate experimental data, preclinical modeling, and statistical analysis to identify trends, reduce risk, and guide portfolio prioritization. 

Machine learning models support predictive target validation, compound design, biomarker discovery, and safety signal identification. AI-driven analytics accelerate candidate refinement and enhance probability of clinical success. 

Pharmacokinetic/pharmacodynamic (PK/PD) modeling and in silico simulations inform dose selection, safety margins, and trial design. Mechanistic and systems-level models reduce uncertainty prior to first-in-human studies. 

Our regulatory team develops integrated strategies for IND submission and global regulatory engagement. We ensure compliance with GLP, GMP, and ICH standards while maintaining proactive dialogue with regulatory authorities. 

We develop scalable, GMP-compliant manufacturing processes with validated analytical methods and stability programs. CMC strategy ensures product consistency, quality assurance, and readiness for clinical development.